Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications.
作者信息
Buonaguro L, Tornesello M L, Buonaguro F M
机构信息
Laboratory of Viral Oncogenesis and Immunotherapy & AIDS Reference Center, Ist. Naz. Tumori Fond. G. Pascale, Via Mariano Semmola, 1, 80131 Naples, Italy.
出版信息
J Virol. 2007 Oct;81(19):10209-19. doi: 10.1128/JVI.00872-07. Epub 2007 Jul 18.
Abstract
摘要
相似文献
1
Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications.
J Virol. 2007 Oct;81(19):10209-19. doi: 10.1128/JVI.00872-07. Epub 2007 Jul 18.
2
Diversity, drug resistance, and the epidemic of subtype C HIV-1 in Africa.
J Infect Dis. 2006 Sep 15;194 Suppl 1:S45-50. doi: 10.1086/505353.
3
The genetic variability of HIV-1 and its implications.
Transfus Clin Biol. 2001 Jun;8(3):222-5. doi: 10.1016/s1246-7820(01)00131-8.
4
The emerging genetic diversity of HIV. The importance of global surveillance for diagnostics, research, and prevention.
JAMA. 1996 Jan 17;275(3):210-6.
5
Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen.
Antimicrob Agents Chemother. 2006 Jun;50(6):2210-3. doi: 10.1128/AAC.01447-05.
6
HIV-1 genetic diversity and genotypic drug susceptibility in the Republic of Georgia.
AIDS Res Hum Retroviruses. 2006 May;22(5):470-6. doi: 10.1089/aid.2006.22.470.
7
The challenge of HIV-1 subtype diversity.
N Engl J Med. 2008 Apr 10;358(15):1590-602. doi: 10.1056/NEJMra0706737.
8
Virus from 1959 sample marks early years of HIV.
Science. 1998 Feb 6;279(5352):801. doi: 10.1126/science.279.5352.801.
9
Update on the human immunodeficiency virus.
Med Mal Infect. 2013 May;43(5):177-84. doi: 10.1016/j.medmal.2013.03.001. Epub 2013 Apr 28.
10
Moderate prevalence of transmitted drug resistance and high HIV-1 genetic diversity in patients from Mato Grosso State, Central Western Brazil.
J Med Virol. 2011 Aug;83(8):1301-7. doi: 10.1002/jmv.22128.
引用本文的文献
1
Topolow: a mapping algorithm for antigenic cross-reactivity and binding affinity assays.
Bioinformatics. 2025 Jul 1;41(7). doi: 10.1093/bioinformatics/btaf372.
2
Challenges in Elucidating HIV-1 Genetic Diversity in the Middle East and North Africa: A Review Based on a Systematic Search.
Viruses. 2025 Feb 27;17(3):336. doi: 10.3390/v17030336.
3
Accelerated cognitive aging in chronically infected HIV-1 positive individuals despite effective long-term antiretroviral therapy.
Metab Brain Dis. 2024 Nov 21;40(1):32. doi: 10.1007/s11011-024-01458-w.
4
Drug Discovery and Exploration of Heterocycles for the Development of Anti-HIV Agents.
Infect Disord Drug Targets. 2025;25(3):e18715265290911. doi: 10.2174/0118715265290911240611072422.
5
The emergence and circulation of human immunodeficiency virus (HIV)-1 subtype C.
J Med Microbiol. 2024 May;73(5). doi: 10.1099/jmm.0.001827.
6
Natural Polymorphisms D60E and I62V Stabilize a Closed Conformation in HIV-1 Protease in the Absence of an Inhibitor or Substrate.
Viruses. 2024 Feb 2;16(2):236. doi: 10.3390/v16020236.
7
High Genetic Diversity of HIV-1 and Active Transmission Clusters among Male-to-Male Sexual Contacts (MMSCs) in Zhuhai, China.
Viruses. 2023 Sep 18;15(9):1947. doi: 10.3390/v15091947.
8
HIV-1 Tat amino acid residues that influence Tat-TAR binding affinity: a scoping review.
BMC Infect Dis. 2023 Mar 17;23(1):164. doi: 10.1186/s12879-023-08123-0.
9
Unique profile of predominant CCR5-tropic in CRF07_BC HIV-1 infections and discovery of an unusual CXCR4-tropic strain.
Front Immunol. 2022 Sep 23;13:911806. doi: 10.3389/fimmu.2022.911806. eCollection 2022.
10
Design, Synthesis, Docking Study, and Biological Evaluation of 4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbohydrazide Derivatives as Anti-HIV-1 and Antibacterial Agents.
Iran J Pharm Res. 2022 May 4;21(1):e126562. doi: 10.5812/ijpr-126562. eCollection 2022 Dec.
本文引用的文献
1
Genetic and phylogenetic evolution of HIV-1 in a low subtype heterogeneity epidemic: the Italian example.
Retrovirology. 2007 May 21;4:34. doi: 10.1186/1742-4690-4-34.
2
The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes.
J Immunol. 2007 Apr 1;178(7):4424-35. doi: 10.4049/jimmunol.178.7.4424.
3
Evolution of the HIV-1 V3 region in the Italian epidemic.
New Microbiol. 2007 Jan;30(1):1-11.
4
Evaluation of performance across the dynamic range of the Abbott RealTime HIV-1 assay as compared to VERSANT HIV-1 RNA 3.0 and AMPLICOR HIV-1 MONITOR v1.5 using serial dilutions of 39 group M and O viruses.
J Virol Methods. 2007 Apr;141(1):49-57. doi: 10.1016/j.jviromet.2006.11.026. Epub 2006 Dec 20.
5
Molecular and phylogenetic analysis of HIV-1 variants circulating among injecting drug users in Mashhad-Iran.
Infect Agent Cancer. 2006 Sep 19;1:4. doi: 10.1186/1750-9378-1-4.
6
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.
J Infect Dis. 2006 Dec 15;194(12):1650-60. doi: 10.1086/509259. Epub 2006 Nov 8.
7
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector.
J Infect Dis. 2006 Dec 15;194(12):1638-49. doi: 10.1086/509258. Epub 2006 Nov 8.
8
Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.
Virology. 2007 Mar 30;360(1):218-34. doi: 10.1016/j.virol.2006.10.017. Epub 2006 Nov 13.
9
Genetic and phylogenetic characterization of structural genes from non-B HIV-1 subtypes in Italy.
AIDS Res Hum Retroviruses. 2006 Oct;22(10):1045-51. doi: 10.1089/aid.2006.22.1045.
10
Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004.
AIDS. 2006 Oct 24;20(16):W13-23. doi: 10.1097/01.aids.0000247564.73009.bc.
Zotero 插件